BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM. Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. Am J Respir Crit Care Med 2019;199:947-51. [PMID: 30428263 DOI: 10.1164/rccm.201807-1273PP] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Dartois V, Sizemore C, Dick T. Editorial: NTM-The New Uber-Bugs. Front Microbiol 2019;10:1299. [PMID: 31249560 DOI: 10.3389/fmicb.2019.01299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Abate G, Stapleton JT, Rouphael N, Creech B, Stout JE, El Sahly HM, Jackson L, Leyva FJ, Tomashek KM, Tibbals M, Watson N, Miller A, Charbek E, Siegner J, Sokol-Anderson M, Nayak R, Dahlberg G, Winokur P, Alaaeddine G, Beydoun N, Sokolow K, Kown NP, Phillips S, Baker AW, Turner N, Walter E, Guy E, Frey S. Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. Clin Infect Dis 2021;72:1127-37. [PMID: 32198521 DOI: 10.1093/cid/ciaa252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ganapathy US, Del Rio RG, Cacho-Izquierdo M, Ortega F, Lelièvre J, Barros-Aguirre D, Lindman M, Dartois V, Gengenbacher M, Dick T. A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity. Antimicrob Agents Chemother 2021:AAC. [PMID: 33558292 DOI: 10.1128/AAC.02420-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dohál M, Porvazník I, Solovič I, Mokrý J. Whole Genome Sequencing in the Management of Non-Tuberculous Mycobacterial Infections. Microorganisms 2021;9:2237. [PMID: 34835363 DOI: 10.3390/microorganisms9112237] [Reference Citation Analysis]
5 Lipman M, Cleverley J, Fardon T, Musaddaq B, Peckham D, van der Laan R, Whitaker P, White J. Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK. BMJ Open Respir Res 2020;7:e000591. [PMID: 32565445 DOI: 10.1136/bmjresp-2020-000591] [Reference Citation Analysis]
6 Aksamit TR. One Step Closer: Nontuberculous Mycobacterial Pulmonary Disease and Predicted Mortality-The BACES Score. Am J Respir Crit Care Med 2021;203:163-4. [PMID: 32835508 DOI: 10.1164/rccm.202008-3051ED] [Reference Citation Analysis]
7 Yam YK, Alvarez N, Go ML, Dick T. Extreme Drug Tolerance of Mycobacterium abscessus "Persisters". Front Microbiol 2020;11:359. [PMID: 32194537 DOI: 10.3389/fmicb.2020.00359] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
8 Larsen MH, Lacourciere K, Parker TM, Kraigsley A, Achkar JM, Adams LB, Dupnik KM, Hall-Stoodley L, Hartman T, Kanipe C, Kurtz SL, Miller MA, Salvador LCM, Spencer JS, Robinson RT. The Many Hosts of Mycobacteria 8 (MHM8): A conference report. Tuberculosis (Edinb) 2020;121:101914. [PMID: 32279870 DOI: 10.1016/j.tube.2020.101914] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Negatu DA, Beuchel A, Madani A, Alvarez N, Chen C, Aragaw WW, Zimmerman MD, Laleu B, Gengenbacher M, Dartois V, Imming P, Dick T. Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus. Antimicrob Agents Chemother 2021;65:e0067621. [PMID: 34001512 DOI: 10.1128/AAC.00676-21] [Reference Citation Analysis]
10 Keefe BF, Bermudez LE. Environment in the lung of cystic fibrosis patients stimulates the expression of biofilm phenotype in Mycobacterium abscessus. J Med Microbiol 2022;71. [PMID: 35014948 DOI: 10.1099/jmm.0.001467] [Reference Citation Analysis]
11 Larsen SE, Reese VA, Pecor T, Berube BJ, Cooper SK, Brewer G, Ordway D, Henao-Tamayo M, Podell BK, Baldwin SL, Coler RN. Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models. Sci Rep 2021;11:9040. [PMID: 33907221 DOI: 10.1038/s41598-021-88291-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Furuuchi K, Seto S, Nakamura H, Hikichi H, Miyabayashi A, Wakabayashi K, Mizuno K, Oka T, Morimoto K, Hijikata M, Keicho N. Novel Screening System of Virulent Strains for the Establishment of a Mycobacterium avium Complex Lung Disease Mouse Model Using Whole-Genome Sequencing. Microbiol Spectr 2022;:e0045122. [PMID: 35579455 DOI: 10.1128/spectrum.00451-22] [Reference Citation Analysis]
13 Han SA, Jhun BW, Kim SY, Moon SM, Yang B, Kwon OJ, Daley CL, Shin SJ, Koh WJ. miRNA Expression Profiles and Potential as Biomarkers in Nontuberculous Mycobacterial Pulmonary Disease. Sci Rep 2020;10:3178. [PMID: 32081976 DOI: 10.1038/s41598-020-60132-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Parker HA, Forrester L, Kaldor CD, Dickerhof N, Hampton MB. Antimicrobial Activity of Neutrophils Against Mycobacteria. Front Immunol 2021;12:782495. [PMID: 35003097 DOI: 10.3389/fimmu.2021.782495] [Reference Citation Analysis]
15 Dick T. Rifabutin: A Repurposing Candidate for Mycobacterium abscessus Lung Disease. Front Microbiol 2020;11:371. [PMID: 32174907 DOI: 10.3389/fmicb.2020.00371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Degiacomi G, Sammartino JC, Chiarelli LR, Riabova O, Makarov V, Pasca MR. Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients. Int J Mol Sci 2019;20:E5868. [PMID: 31766758 DOI: 10.3390/ijms20235868] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
17 Ganapathy US, Dartois V, Dick T. Repositioning rifamycins for Mycobacterium abscessus lung disease. Expert Opin Drug Discov 2019;14:867-78. [PMID: 31195849 DOI: 10.1080/17460441.2019.1629414] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
18 Salfinger M, Somoskovi A. Is It Time to Move the Goalposts? Clin Infect Dis 2021;72:1138-40. [PMID: 32198513 DOI: 10.1093/cid/ciaa250] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Yuan Z, Prasla Z, Lee FE, Bedi B, Sutliff RL, Sadikot RT. MicroRNA-155 Modulates Macrophages' Response to Non-Tuberculous Mycobacteria through COX-2/PGE2 Signaling. Pathogens 2021;10:920. [PMID: 34451384 DOI: 10.3390/pathogens10080920] [Reference Citation Analysis]
20 Gloag ES, Wozniak DJ, Stoodley P, Hall-Stoodley L. Mycobacterium abscessus biofilms have viscoelastic properties which may contribute to their recalcitrance in chronic pulmonary infections. Sci Rep 2021;11:5020. [PMID: 33658597 DOI: 10.1038/s41598-021-84525-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Johansen MD, Daher W, Roquet-Banères F, Raynaud C, Alcaraz M, Maurer FP, Kremer L. Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus. Antimicrob Agents Chemother 2020;64:e00363-20. [PMID: 32816730 DOI: 10.1128/AAC.00363-20] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
22 Fifor A, Krukowski K, Honda JR. Sex, ancestry, senescence, and aging (SAnSA) are stark drivers of nontuberculous mycobacterial pulmonary disease. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 2022;26:100297. [DOI: 10.1016/j.jctube.2022.100297] [Reference Citation Analysis]
23 Ganapathy US, Del Río RG, Cacho-Izquierdo M, Ortega F, Lelièvre J, Barros-Aguirre D, Aragaw WW, Zimmerman MD, Lindman M, Dartois V, Gengenbacher M, Dick T. A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother 2021;65:e0151421. [PMID: 34606340 DOI: 10.1128/AAC.01514-21] [Reference Citation Analysis]
24 Rinaldi F, Hanieh PN, Sennato S, De Santis F, Forte J, Fraziano M, Casciardi S, Marianecci C, Bordi F, Carafa M. Rifampicin-Liposomes for Mycobacterium abscessus Infection Treatment: Intracellular Uptake and Antibacterial Activity Evaluation. Pharmaceutics 2021;13:1070. [PMID: 34371761 DOI: 10.3390/pharmaceutics13071070] [Reference Citation Analysis]
25 Chin KL, Sarmiento ME, Alvarez-Cabrera N, Norazmi MN, Acosta A. Pulmonary non-tuberculous mycobacterial infections: current state and future management. Eur J Clin Microbiol Infect Dis 2020;39:799-826. [PMID: 31853742 DOI: 10.1007/s10096-019-03771-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
26 Horne D, Skerrett S. Recent advances in nontuberculous mycobacterial lung infections. F1000Res 2019;8:F1000 Faculty Rev-1710. [PMID: 31602293 DOI: 10.12688/f1000research.20096.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
27 Weathered C, Pennington K, Escalante P, Pienaar E. The Role of Biofilms, Bacterial Phenotypes, and Innate Immune Response in Mycobacterium avium Colonization to Infection. J Theor Biol 2021;:110949. [PMID: 34717938 DOI: 10.1016/j.jtbi.2021.110949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]